Pseudomonas aeruginosa and cystic fibrosis: Antibiotic therapy and the science behind the magic

Canadian Journal of Infectious Diseases

Volumn 8, Issue 6, 1997, Pages 335-342

  MacDonald, Noni E ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Antibiotic therapy; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; CARBENICILLIN; CEFTAZIDIME; CLOXACILLIN; GENTAMICIN; PLACEBO; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BRONCHIECTASIS; CYSTIC FIBROSIS; HUMAN; IMMOTILE CILIA SYNDROME; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; PATHOGENESIS; PSEUDOMONAS AERUGINOSA; REVIEW; X LINKED AGAMMAGLOBULINEMIA;

EID: 0031458897     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/617690     Document Type: Review

References (50)

1. Tizzano EF, Buchwald M. Cystic fibrosis: Beyond the gene to therapy. J Pediatr 1992;120:337-49.
2. Colin AA, Wohl MEB. Cystic fibrosis. Pediatr Rev 1994;15:192-200.
3. Barasch J, Al-Awqati Q. Defective acidification of the biosynthetic pathway in cystic fibrosis. J Cell Sci 1993;S17:229-33.
4. MacDonald NE, Corey M, Morrison R. General approach to cystic fibrosis pulmonary infection: Canada. In: Marks M, ed. Cystic Fibrosis Pulmonary Infection - Lessons From Around the World. Basel: Birkhauser Verlag AG, 1996:111-7.
5. Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? J Pediatr 1980;97:144-7.
6. Wientzen R, Prestidge CB, Kramer RI, McCracken GH, Nelson JD. Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy. Am J Dis Child 1980;134:1134-8.
7. Gold R, Carpenter S, Heurter H, Corey M, Levison H. Randomized trial of ceftaxidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1987;111:907-13.
8. MacDonald NE, Anas NG, Peterson RG, Schwartz RH, Brooks JG, Powell KR. Renal clearance of gentamycin in cystic fibrosis. J Pediatr 1983;103:985-90.
9. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: A prospective controlled study. J Pediatr 1984;105:117-24.
10. Reed MD, Stern RC, Bertino JS, Myers CM, Yamashita TS, Blumer JL. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr 1984;104:303-7.
11. Goldmann DA, Klinger JD. Pseudomonas cepacia: Biology, mechanisms of virulence, epidemiology. J Pediatr 1986;108:806-12.
12. Pedersen SS, Jensen T, Pressler T, Hoiby N, Rosendal K. Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection? Acta Paediatr Scand 1986;75:840-5.
13. Motoyama KE. Evaluation of mist tent therapy in cystic fibrosis using maximal expiratory flow-volume curves. Pediatr 1972;50:299-306.
14. Lewiston NJ. Bronchiectasis in childhood. Pediatr Clin North Am 1984;31:865-77.
15. Tannenberg J, Pinner MA. Atelectasis and bronchiectasis. An experimental study concerning their relationship. J Thorac Surg 1942;11:571-616.
16. Cheng K-K. The experimental production of bronchiectasis in rats. J Pathol Bacteriol 1954;57:89-98.
17. Bedrossian CWM, Greenberg SD, Singer DB, Hansen JJ, Rosenberg HS. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976;7:195-204.
18. Nathanson I, Conboy K, Murphy S, Afshani E, Kuhn JP. Ultrafast computerized tomography of the chest in cystic fibrosis: A new scoring system. Pediatr Pulmonol 1991;11:81-6.
19. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571-2.
20. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
21. Ramsey BW, Wentz KR, Smith AL, et al. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991;144:331-7.
22. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
23. Krivan HC, Roberts DD, Ginsburg V. Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAcβ1-4Gal found in some glycolipids. Proc Natl Acad Sci USA 1988;85:6157-61.
24. Saiman L, Prince A. Pseudomonas aeruginosa pili bind to AsialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest 1993;92:1875-80.
25. Boat TF, Cheng PW. Biochemistry of airway mucus secretions. Fed Proc 1980;39:3067-74.
26. Barasch J, Kiss B, Prince A, Saiman L, Guenert D, Al-Awqati Q. Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991;352:70-3.
27. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 1995;92:3019-23.
28. Cacalano G, Kays M, Saiman L, Prince A. Production of the Pseudomonas aeruginosa neuraminidase is increased under hyperosmolar conditions and is required by genes involved in alginate expression. J Clin Invest 1992;89:1866-74.
29. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251-4.
30. Zar H, Saiman L, Quittell L, Prince A. Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 1995;126:230-3.
31. Kubesch P, Dork T, Wulbrand U, et al. Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis. Lancet 1993;341:189-93.
32. Ramphal R, Pyle M. Evidence for mucins and sialic acid as receptors for Pseudomonas aeruginosa in the lower respiratory tract. Infect Immun 1983;41:339-44.
33. Sajjan U, Reisman J, Doig P, Irvin RT, Forstner G, Forstner J. Binding of nonmucoid Pseudomonas aeruginosa to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest 1992;89:657-65.
34. Reddy MS. Human tracheobronchial mucin: Purification and binding to Pseudomonas aeruginosa. Infect Immun 1992;60:1530-5.
35. Smith JJ, Travis SM, Greenberg P, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-36.
36. Quinton PM. Viscosity versus composition in airway pathology. Am J Respir Crit Care Med 1994;149:6-7.
37. Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet 1993;341:1065-74.
38. Speert DP. Host defenses in patients with cystic fibrosis: Modulation by Pseudomonas aeruginosa. Surv Synth Path Res 1985;4:14-33.
39. Wilson R, Sykes DA, Currie D, Cole PJ. Beat frequency of cilia from sites of purulent infection. Thorax 1986;41:453-8.
40. Pier GB, Grout M, Tanweer SZ, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996;271:64-7.
41. Fleiszig SM, Zaidi TS, Pier GB. Pseudomonas aeruginosa invasion of and multiplication with corneal epithelial cells in vitro. Infect Immun 1995;63:4072-7.
42. Barghouthi S, Everett KD, Speert DP. Nonopsonic phagocytosis of Pseudomonas aeruginosa requires facilitated transport of D-glucose by macrophages. J Immunol 1995;154:3420-8.
43. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-21.
44. Grimwood K, To M, Semple RA, Rabin HR, Sokol PA, Woods DE. Elevated exoenzyme expression by Pseudomonas aeruginosa is correlated with exacerbations of lung disease in cystic fibrosis. Pediatr Pulmonol 1993;15:135-9.
45. Grimwood K, To M, Rabin H, Woods DE. Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations. Antimicrob Agents Chemother 1989;33:41-7.
46. Geers TA, Baker NR. The effect of sublethal levels of antibiotics on the pathogenicity of Pseudomonas aeruginosa for tracheal tissue. J Antimicrob Chemother 1987;19:569-78.
47. Cantin A, Woods DE. Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. J Clin Invest 1993;91:38-45.
48. Howard M, Frizzel RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Med 1996;2:467-9.
49. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-88.
50. Moss RB. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin Infect Dis 1995;21:839-51.